Lead Product(s): Sulfatinib
Therapeutic Area: Oncology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2020
The IDMC recommended that the study stops early as the pre-defined primary endpoint of progression free survival had already been met.